Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Modeling the Number of People Infected With SARS-COV-2 From Wastewater Viral Load in Northwest Spain

  • Vallejo, J. A.
  • Trigo Tasende, Noelia
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Vaamonde, Manuel
  • Tarrío-Saavedra, Javier
  • Reif López, Rubén
  • Ladra, Susana
  • Rodiño-Janeiro, Bruno Kotska
  • Nasser-Ali, Mohammed
  • Cid, Ángeles
  • Veiga, María Carmen
  • Acevedo, Antón
  • Lamora, Carlos
  • Bou, Germán
  • Cao, Ricardo
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] The quantification of the SARS-CoV-2 RNA load in wastewater has emerged as a useful tool to monitor COVID–19 outbreaks in the community. This approach was implemented in the metropolitan area of A Coruña (NW Spain), where wastewater from a treatment plant was analyzed to track the epidemic dynamics in a population of 369,098 inhabitants. Viral load detected in the wastewater and the epidemiological data from A Coruña health system served as main sources for statistical models developing. Regression models described here allowed us to estimate the number of infected people (R2 = 0.9), including symptomatic and asymptomatic individuals. These models have helped to understand the real magnitude of the epidemic in a population at any given time and have been used as an effective early warning tool for predicting outbreaks in A Coruña municipality. The methodology of the present work could be used to develop a similar wastewater-based epidemiological model to track the evolution of the COVID–19 epidemic anywhere in the world where centralized water-based sanitation systems exist., This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120 and INV05921 to MP], the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 funded by the ISCIII, Spain - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant numbers PI15/00860 to GB, PI17/01482 and PI20/00413 to MP], the GAIN, Xunta de Galicia, Spain [grant number IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2017/58 to SL, ED431G 2019/01 to RC and SL, and ED431C 2017/66 to MCV], MINECO, Spain [grant number MTM2017-82724-R to RC], Ministerio de Ciencia e Innovación, Spain [grant number PID2020-113578RB-100 to RC], and the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006 to GB]. The work was also supported by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 - Research and Innovation Framework Programme under grant agreement no 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. Funding for open access charge: Universidade da Coruña/CISUG, EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2017/58, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; ED431C 2017/66
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Global transcriptomic analysis during murine pneumonia infection reveals new virulence factors in Acinetobacter baumannii

  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Conde-Pérez, Kelly
  • Vallejo, J. A.
  • Perina Cedrón, Alejandra
  • Bou, Germán
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] Background: Infections caused by multidrug-resistant pathogens such as Acinetobacter baumannii constitute a major health problem worldwide. In this study we present a global in vivo transcriptomic analysis of A. baumannii isolated from the lungs of mice with pneumonia infection. Methods: Mice were infected with A. baumannii ATCC 17978 and AbH12O-A2 strains and the total bacterial RNA were analyzed by RNA sequencing. Lists of differentially expressed genes were obtained and 14 of them were selected for gene deletion and further analysis. Results: Transcriptomic analysis revealed a specific gene expression profile in A. baumannii during lung infection with upregulation of genes involved in iron acquisition and host invasion. Mutant strains lacking feoA, mtnN, yfgC, basB, hisF, oatA, and bfnL showed a significant loss of virulence in murine pneumonia. A decrease in biofilm formation, adherence to human epithelial cells, and growth rate was observed in selected mutants. Conclusions: This study provides an insight into A. baumannii gene expression profile during murine pneumonia infection. Data revealed that 7 in vivo upregulated genes were involved in virulence and could be considered new therapeutic targets., This work was supported by Instituto de Salud Carlos III (PI15/00860 and PI18/00501 to G. B. and PI14/00059 and PI17/01482 to A. B. and M. P.); Axencia Galega de Innovacion- Consellería de Economía, Emprego e Industria (IN607A 2016/22 to G. B); Spanish Network for Research in Infectious Diseases and European Development Regional Fund (REIPI RD16/0016/006 and FI18/00315 to J. C. V.-U); M. M.-G. was supported by the Spanish Society of Clinical Microbiology and Infectious Diseases (Clara Roy grant); and K. C.-P. was supported by the Spanish Association Against Cancer.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Bellés, Alba
  • Vázquez-Ucha, Juan Carlos
  • Arca-Suárez, Jorge
  • Fernández-Lozano, Carlos
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Carbapenem resistance is increasing among Gram-negative bacteria, including the genus Acinetobacter. This study aimed to characterize, for the first time, the development of carbapenem resistance in clinical isolates of Acinetobacter junii and Acinetobacter nosocomialis conferred by the acquisition of a plasmid-borne blaOXA-24/40 gene and also to characterize the dissemination of this gene between species of Acinetobacter. Carbapenem-resistant A. nosocomialis HUAV-AN66 and A. junii HUAV-AJ77 strains were isolated in the Arnau de Vilanova Hospital (Spain). The genomes were sequenced, and in silico analysis were performed to characterize the genetic environment and the OXA-24/40 transmission mechanism. Antibiotic MICs were determined, and horizontal transfer assays were conducted to evaluate interspecies transmission of OXA-24/40. Carbapenems MICs obtained were ≥64 mg/L for HUAV-AN66 and HUAV-AJ77. Genome analysis revealed the presence in both strains of a new plasmid, designated pHUAV/OXA-24/40, harboring the carbapenem-resistance gene blaOXA-24/40 and flanked by sequences XerC/XerD. pHUAV/OXA-24/40 was successfully transferred from A. nosocomialis and A. junii to a carbapenem-susceptible A. baumannii strain, thus conferring carbapenem resistance. A second plasmid (pHUAV/AMG-R) was identified in both clinical isolates for the successful horizontal transfer of pHUAV/OXA-24/40. blaOXA-24/40-carrying plasmids of the GR12 group and showing high identity with pHUAV/OXA-24/40 were identified in at least 8 Acinetobacter species. In conclusion the carbapenemase OXA-24/40 is described for the first time in A. nosocomialis and A. junii. In both isolates the blaOXA-24/40 gene was located in the GR12 pHUAV/OXA-24/40 plasmid. GR12 plasmids are implicated in the dissemination and spread of carbapenem resistance among Acinetobacter species. IMPORTANCE Acinetobacter baumannii is one of the most relevant pathogens in terms of antibiotic resistance. The main resistance mechanisms are the carbapenem-hydrolyzing class D β-lactamases (CHDLs), especially OXA-23 and OXA-24/40. In addition to A. baumannii, there are other species within the genus Acinetobacter, which in general exhibit much lower resistance rates. In this work we characterize for the first time two clinical isolates of Acinetobacter nosocomialis and Acinetobacter junii, isolated in the same hospital, carrying the carbapenemase OXA-24/40 and displaying high resistance rates to carbapenems. By means of bioinformatics analysis we have also been able to characterize the mechanism by which this carbapenemase is horizontally transferred interspecies of Acinetobacter spp. The dissemination of carbapenemase OXA-24/40 between non-baumannii Acinetobacter species is concerning since it prevents the use of most β-lactam antibiotics in the fight against these resistant isolates., This work was supported by Projects PI17/01482 and PI20/01212 awarded to A.B. and PI18/00501 to G.B., all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINF (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607A 2020/05 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to G.B. and IN607D 2021/12 awarded to A.B. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J.A.-S.was financially supported by the Rio Hortega program (ISCIII, CM19/00219), J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and P.G.-S. was financially supported by IN607A 2020/05 Grant (Xunta de Galicia), Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Wastewater early warning system for SARS-CoV-2 outbreaks and variants in a Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Vaamonde, Manuel
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Nasser-Ali, Mohammed
  • Reif López, Rubén
  • Rodiño-Janeiro, Bruno Kotska
  • Fernández-Álvarez, Elisa
  • Iglesias Corrás, Iago
  • Tarrío-Saavedra, Javier
  • Tomás, Laura
  • Gallego-García, Pilar
  • Posada, David
  • Bou, Germán
  • López-de-Ullibarri, Ignacio
  • Cao, Ricardo
  • Susana, Ladra
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract]: Wastewater-based epidemiology has been widely used as a cost-effective method for tracking the COVID-19 pandemic at the community level. Here we describe COVIDBENS, a wastewater surveillance program running from June 2020 to March 2022 in the wastewater treatment plant of Bens in A Coruña (Spain). The main goal of this work was to provide an effective early warning tool based in wastewater epidemiology to help in decision-making at both the social and public health levels. RT-qPCR procedures and Illumina sequencing were used to weekly monitor the viral load and to detect SARS-CoV-2 mutations in wastewater, respectively. In addition, own statistical models were applied to estimate the real number of infected people and the frequency of each emerging variant circulating in the community, which considerable improved the surveillance strategy. Our analysis detected 6 viral load waves in A Coruña with concentrations between 103 and 106 SARS-CoV-2 RNA copies/L. Our system was able to anticipate community outbreaks during the pandemic with 8-36 days in advance with respect to clinical reports and, to detect the emergence of new SARS-CoV-2 variants in A Coruña such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529 and BA.2) in wastewater with 42, 30, and 27 days, respectively, before the health system did. Data generated here helped local authorities and health managers to give a faster and more efficient response to the pandemic situation, and also allowed important industrial companies to adapt their production to each situation. The wastewater-based epidemiology program developed in our metropolitan area of A Coruña (Spain) during the SARS-CoV-2 pandemic served as a powerful early warning system combining statistical models with mutations and viral load monitoring in wastewater over time., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding for open access charge: Universidade da Coruña/CISUG. This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120, INV05921, and INV148721 to MP], by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to GB, PI17/01482, and PI20/00413 to MP], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2021/53 to SL and ED431G 2019/01 and COV20/00604 to RC and SL, by Ministry of Economic Affairs and Digital Transformation (MINECO), Spain [grant references MTM2017-82724-R to RC], by the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0006 to GB], by the “Innova Saúde” Program, (INNOVAMICROLAB project) co-founded by the Galician Healthcare Service (SERGAS) and the Spanish Ministry of Science and Innovation, and by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. DP was funded by grant EPICOVIGAL FONDO SUPERA-COVID19 from Banco Santander-CSIC-CRUE, Spain, and grant CT850A-2 from (Health Knowledge Agency) ACIS SERGAS from the Consellería de Sanidade of Xunta de Galicia, Spain., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antisense inhibition of lpxB gene expression in Acinetobacter baumannii by peptide-PNA conjugates and synergy with colistin

  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Conde-Pérez, Kelly
  • Bou, Germán
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] Background: LpxB is an enzyme involved in the biosynthesis pathway of lipid A, a component of LPS. Objectives: To evaluate the lpxB gene in Acinetobacter baumannii as a potential therapeutic target and to propose antisense agents such as peptide nucleic acids (PNAs) as a tool to combat bacterial infection, either alone or in combination with known antimicrobial therapies. Methods: RNA-seq analysis of the A. baumannii ATCC 17978 strain in a murine pneumonia model was performed to study the in vivo expression of lpxB. Protein expression was studied in the presence or absence of anti-lpxB (KFF)3K-PNA (pPNA). Time-kill curve analyses and protection assays of infected A549 cells were performed. The chequerboard technique was used to test for synergy between pPNA and colistin. A Galleria mellonella infection model was used to test the in vivo efficacy of pPNA. Results: The lpxB gene was overexpressed during pneumonia. Treatment with a specific pPNA inhibited LpxB expression in vitro, decreased survival of the ATCC 17978 strain and increased the survival rate of infected A549 cells. Synergy was observed between pPNA and colistin in colistin-susceptible strains. In vivo assays confirmed that a combination treatment of anti-lpxB pPNA and colistin was more effective than colistin in monotherapy. Conclusions: The lpxB gene is essential for A. baumannii survival. Anti-lpxB pPNA inhibits LpxB expression, causing bacterial death. This pPNA showed synergy with colistin and increased the survival rate in G. mellonella. The data suggest that antisense pPNA molecules blocking the lpxB gene could be used as antibacterial agents., This study was funded by projects PI15/00860 and PI18/00501 to G.B., CP13/00226 to A.B., and PI14/00059 and PI17/01482 to A.B. and M.P. (Instituto de Salud Carlos III). The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) to G.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund ‘A way to achieve Europe’ and the operative programme Intelligent Growth 2014–2020. J.C.V.U. was financially supported by the Miguel Servet Programme (ISCIII, Spain CP13/00226) and the pFIS Programme (FI18/00315) and M.M.G. was financially supported by a Clara Roy grant (SEIMC) and K.C.P. by IN607A 2016/22.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antimicrobial Diterpene Alkaloids from an Agelas citrina Sponge Collected in the Yucatán Peninsula

  • Pech-Puch, Dawrin
  • Forero, Abel M.
  • Fuentes-Monteverde, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • Martínez Guitián, Marta
  • González-Salas, Carlos
  • Guillén-Hernández, Sergio
  • Villegas-Hernández, Harold
  • Beceiro Casas, Alejandro
  • Griesinger, Christian
  • Rodríguez, Jaime
  • Jiménez, Carlos
[Abstract] Three new diterpene alkaloids, (+)-8-epiagelasine T (1), (+)-10-epiagelasine B (2), and (+)-12-hydroxyagelasidine C (3), along with three known compounds, (+)-ent-agelasine F (4), (+)-agelasine B (5), and (+)-agelasidine C (6), were isolated from the sponge Agelas citrina, collected on the coasts of the Yucatán Peninsula (Mexico). Their chemical structures were elucidated by 1D and 2D NMR spectroscopy, HRESIMS techniques, and a comparison with literature data. Although the synthesis of (+)-ent-agelasine F (4) has been previously reported, this is the first time that it was isolated as a natural product. The evaluation of the antimicrobial activity against the Gram-positive pathogens Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis showed that all of them were active, with (+)-10-epiagelasine B (2) being the most active compound with an MIC in the range of 1–8 µg/mL. On the other hand, the Gram-negative pathogenes Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae were also evaluated, and only (+)-agelasine B (5) showed a moderate antibacterial activity with a MIC value of 16 μg/mL., This work was supported by grants RTI2018-093634-B-C22 from the State Agency for Research (AEI) of Spain, cofunded by the FEDER Programme from the European Union (MCIN/AEI/10.13039/501100011033/FEDER) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). This work was supported by Projects PI17/01482 and PI20/01212 awarded to AB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2017–2020 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607D 2021/12 (GAIN-Agencia Gallega de Innovación—Consellería de Economía, Emprego e Industria) awarded to AB. The study was also funded by projects GRC2018/039 from Xunta de Galicia. Dawrin Pech-Puch received his postdoctoral fellowship from the National Council of Science and Technology (CONACYT) of Mexico. This work was supported by the Max Planck Society and the DFG (Gr1211/19-1)/CAPES 418729698 project, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; GRC2018/039, Deutsche Forschungsgemeinschaft = German Research Foundation; Gr1211/19-1, Brasil. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); 418729698
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Selection of AmpC β-Lactamase variants and Metallo-β-Lactamases leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections

  • Ruedas-López, Alba
  • Alonso-García, Isaac
  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Vallejo, J. A.
  • Fraile-Ribot, Pablo Arturo
  • Fernández-Pérez, Begoña
  • Velasco, David
  • Gutiérrez-Urbón, José María
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Bou, Germán
[Abstract] Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection. Fifteen isolates showing ceftolozane-tazobactam and ceftazidime-avibactam resistance were evaluated. Clinical conditions, previous positive cultures, and β-lactams received in the previous month were reviewed for each patient. MICs were determined by broth microdilution. Multilocus sequence types (MLSTs) and resistance mechanisms were determined using short- and long-read whole-genome sequencing (WGS). The impact of Pseudomonas-derived cephalosporinases (PDCs) on β-lactam resistance was demonstrated by cloning into an ampC-deficient PAO1 derivative (PAOΔC) and construction of 3D models. Genetic support of acquired β-lactamases was determined in silico from high-quality hybrid assemblies. In most cases, the isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Seven isolates from different sequence types (STs) owed their β-lactam resistance to chromosomal mutations and all displayed specific substitutions in PDC: Phe121Leu and Gly222Ser, Pro154Leu, Ala201Thr, Gly214Arg, ΔGly203-Glu219, and Glu219Lys. In the other eight isolates, the ST175 clone was overrepresented (6 isolates) and associated with IMP-28 and IMP-13, whereas two ST1284 isolates produced VIM-2. The cloned PDCs conferred enhanced cephalosporin resistance. The 3D PDC models revealed rearrangements affecting residues involved in cephalosporin hydrolysis. Carbapenemases were chromosomal (VIM-2) or plasmid-borne (IMP-28, IMP-13) and associated with class-1 integrons located in Tn402-like transposition modules. Our findings highlighted that cephalosporin/β-lactamase inhibitors are potential selectors of MDR/XDR P. aeruginosa strains producing PDC variants or metallo-β-lactamases. Judicious use of these agents is encouraged., his work was supported by Projects and PI18/00501 to GB PI17/01482 and PI20/01212 awarded to AB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013 to 2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB and IN607D 2021/12 awarded to AB. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013 to 2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth from 2014 to 2020. CGB acknowledges the financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29) and Centro singular de investigación de Galicia accreditation from 2019 to 2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF). CLM was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN607A 2020/05 Grant (Xunta de Galicia). JCVU was financially supported by the pFIS program (ISCIII, PI17/01482). M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006). JAS was financially supported by the Rio Hortega program (ISCIII-SERGAS, CM19/00219).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification

  • Gato, Eva
  • Guijarro-Sánchez, Paula
  • Alonso-García, Isaac
  • Pedraza-Merino, Rosa
  • Conde, Adrián
  • Lence, Emilio
  • Rumbo-Feal, Soraya
  • Peña-Escolano, Andrea
  • Lasarte-Monterrubio, Cristina
  • Blanco Martín, Tania
  • Fernández González, Ana
  • Fernández-López, María del Carmen
  • Maceiras, Romina
  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Martínez-Martínez, Luis
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Objectives: In order to inform and anticipate potential strategies aimed at combating KPC-producing Klebsiella pneumoniae infections, we analysed imipenem/relebactam and ceftazidime/avibactam single-step mutant frequencies, resistance development trajectories, differentially selected resistance mechanisms and their associated fitness cost using four representative high-risk K. pneumoniae clones. Methods: Mutant frequencies and mutant preventive concentrations were determined using agar plates containing incremental concentrations of β-lactam/β-lactamase inhibitor. Resistance dynamics were determined through incubation for 7 days in 10 mL MH tubes containing incremental concentrations of each antibiotic combination up to their 64 × baseline MIC. Two colonies per strain from each experiment were characterized by antimicrobial susceptibility testing, whole genome sequencing and competitive growth assays (to determine in vitro fitness). KPC variants associated with imipenem/relebactam resistance were characterized by cloning and biochemical experiments, atomic models and molecular dynamics simulation studies. Results: Imipenem/relebactam prevented the emergence of single-step resistance mutants at lower concentrations than ceftazidime/avibactam. In three of the four strains evaluated, imipenem/relebactam resistance development emerged more rapidly, and in the ST512/KPC-3 clone reached higher levels compared to baseline MICs than for ceftazidime/avibactam. Lineages evolved in the presence of ceftazidime/avibactam showed KPC substitutions associated with high-level ceftazidime/avibactam resistance, increased imipenem/relebactam susceptibility and low fitness costs. Lineages that evolved in the presence of imipenem/relebactam showed OmpK36 disruption, KPC modifications (S106L, N132S, L167R) and strain-specific substitutions associated with imipenem/relebactam resistance and high fitness costs. Imipenem/relebactam-selected KPC derivatives demonstrated enhanced relebactam resistance through important changes affecting relebactam recognition and positioning. Conclusions: Our findings anticipate potential resistance mechanisms affecting imipenem/relebactam during treatment of KPC-producing K. pneumoniae infections., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support (to G.B.) and relebactam. This work was also supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 and PI21/00704 for G.B.) integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III (ISCIII), CIBERINFEC (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe.’ The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.). PGS was financially supported by IN606A-2021/021. I.A.-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/ 029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). Financial support from the Spanish Agency of Research (PID2019-105512RB-I00/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF) is gratefully acknowledged. AC acknowledges Banco Santander for his fellowship. We are also grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In-Depth Analysis of the Role of the Acinetobactin Cluster in the Virulence of Acinetobacter baumannii

  • Conde-Pérez, Kelly
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Ageitos, Lucía
  • Rumbo-Feal, Soraya
  • Martínez Guitián, Marta
  • Trigo Tasende, Noelia
  • Rodríguez, Jaime
  • Bou, Germán
  • Jiménez, Carlos
  • Beceiro Casas, Alejandro
  • Poza, Margarita
[Abstract] Acinetobacter baumannii is a multidrug-resistant pathogen that represents a serious threat to global health. A. baumannii possesses a wide range of virulence factors that contribute to the bacterial pathogenicity. Among them, the siderophore acinetobactin is one of the most important, being essential for the development of the infection. In this study we performed an in-depth analysis of the acinetobactin cluster in the strain A. baumannii ATCC 17978. For this purpose, nineteen individual isogenic mutant strains were generated, and further phenotypical analysis were performed. Individual mutants lacking the biosynthetic genes entA, basG, basC, basD, and basB showed a significant loss in virulence, due to the disruption in the acinetobactin production. Similarly, the gene bauA, coding for the acinetobactin receptor, was also found to be crucial for the bacterial pathogenesis. In addition, the analysis of the ΔbasJ/ΔfbsB double mutant strain demonstrated the high level of genetic redundancy between siderophores where the role of specific genes of the acinetobactin cluster can be fulfilled by their fimsbactin redundant genes. Overall, this study highlights the essential role of entA, basG, basC, basD, basB and bauA in the pathogenicity of A. baumannii and provides potential therapeutic targets for the design of new antivirulence agents against this microorganism., This work was funded by Projects PI15/00860 awarded to GB and PI17/01482 to AB and MP, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB. This work was also supported by Planes Nacionales de I + D + i 2008–2011/2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. This work was also supported by Grant RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union and Xunta de Galicia for the support of Grant ED431E 2018/03 for CICA-INIBIC strategic and the initiative “Seed Projects 2019–2020.” JV-U was financially supported by the ISCIII project FI18/00315, LÁ-F by the ISCIII project PI14/00059 and the IN606B-2018/011, MM-G was financially supported by the Grant Clara Roy (SEIMC, Spanish Society of Clinical Microbiology and Infectious Diseases), KC-P by IN607A 2016/22 and AECC (Asociación Española Contra el Cáncer) predoctoral fellowship and LA by Xunta de Galicia co-funded with the European Social Fund (FSE) of the European Union (ED481A-2019/081), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606B-2018/011, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED481A-2019/081
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

  • Arca-Suárez, Jorge
  • Rodiño-Janeiro, Bruno Kotska
  • Pérez Gómez, Astrid
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Cruz, Fernando
  • Gómez-Garrido, Jéssica
  • Alioto, Tyler S.
  • Álvarez-Tejado, Miguel
  • Gut, Marta
  • Gut, Ivo
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
Comparative study, [Abstract] The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support of RMTs in CPE isolates from Spain. This study included a collection of 468 CPE isolates recovered during 2018 from 32 participating Spanish hospitals. MICs were determined using the broth microdilution method, the agar dilution method (fosfomycin) or MIC gradient strips (plazomicin). All isolates were subjected to hybrid whole-genome sequencing (WGS). Sequence types (STs), core genome phylogenetic relatedness, horizontally acquired resistance mechanisms, plasmid analysis and the genetic environment of RMTs were determined in silico from WGS data in all RMT-positive isolates. Among the 468 CPE isolates evaluated, 24 isolates (5.1%) recovered from nine different hospitals spanning five Spanish regions showed resistance to all aminoglycosides and were positive for an RMT (21 RmtF, 2 ArmA and 1 RmtC). All RMT-producers showed high-level resistance to all aminoglycosides, including plazomicin, and in most cases exhibited an extensively drug-resistant susceptibility profile. The RMT-positive isolates showed low genetic diversity and were global clones of Klebsiella pneumoniae (ST147, ST101, ST395) and Enterobacter cloacae (ST93) bearing blaOXA-48, blaNDM-1 or blaVIM-1 carbapenemase genes. RMTs were harboured in five different multidrug resistance plasmids and linked to efficient mobile genetic elements. Our findings highlight that RMTs are emerging among clinical CPE isolates from Spain and their spread should be monitored to preserve the future clinical utility of aminoglycosides and plazomicin., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to GB and P17/01482 to AB. MG and IG acknowledge the support of the MEIC through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund [MINECO/FEDER, BIO2015-71792-P]. MG and IG also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d'Empresa i Coneixement and the CERCA Programme. Support was also provided by Planes Nacionales de I+D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006] co-financed by the European Regional Development Fund ‘A Way to Achieve Europe’, and the operative Intelligent Growth program 2014–2020. JAS was financially supported by the Fundacion Profesor Novoa Santos through a Post-especialización grant and by the Rio Hortega program [ISCIII-SERGAS, CM19/00219]. MO was financially supported by the Juan Rodés program [ISCIII-SERGAS, JR18/00006]. JCVU was financially supported by the pFIS program [ISCIII, PI17/01482].
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] The pyrrole-imidazoles, a group of alkaloids commonly found in marine sponges belonging to the genus Agelas, display a wide range of biological activities. Herein, we report the first chemical study of the secondary metabolites of the sponge A. dilatata from the coastal area of the Yucatan Peninsula (Mexico). In this study, we isolated eight known alkaloids from an organic extract of the sponge. We used NMR and MS analysis and comparison with existing databases to characterize the alkaloids: ageliferin (1), bromoageliferin (2), dibromoageliferin (3), sceptrin (4), nakamuric acid (5), 4-bromo-1H-pyrrole-2-carboxylic acid (6), 4,5-dibromopyrrole-2-carboxylic acid (7) and 3,7-dimethylisoguanine (8). We also evaluated, for the first time, the activity of these alkaloids against the most problematic multidrug-resistant (MDR) pathogens, i.e., the Gram-negative bacteria Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Bromoageliferin (2) displayed significant activity against P. aeruginosa. Comparison of the antibacterial activity of ageliferins 1–3 (of similar structure) against P. aeruginosa revealed some relationship between structure and activity. Furthermore, in in vitro assays, 2 inhibited growth and biofilm production in clinical strains of P. aeruginosa. Moreover, 2 increased the survival time in an in vivo Galleria mellonella model of infection. The findings confirm bromoageliferin (2) as a potential lead for designing new antibacterial drugs., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, both co-funded by the FEDER Programme from the European Union and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). This work was also funded by Projects PI17/01482 awarded to AB and PI15/00860 to GB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” and operative program Intelligent Growth 2014-2020. The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to GB. D.P.-P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan. Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan. JCVU was financially supported by the pFIS Program (FI18/00315), MMG by a Clara Roy grant (SEIMC) and CLM by IN606A-2019/029, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Building-Scale Wastewater-Based Epidemiology for SARS-CoV-2 Surveillance at Nursing Homes in A Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Nasser-Ali, Mohammed
  • Tarrío-Saavedra, Javier
  • Barbeito, Inés
  • Cao, Ricardo
  • Ladra, Susana
  • Bou, Germán
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] Wastewater-based epidemiology (WBE) has become an effective tool in the surveillance of infectious diseases such as COVID-19. In this work, we performed a brief study of monitoring the SARS-CoV-2 viral load in wastewater from six nursing homes located in the metropolitan area of A Coruña (Spain) between December 2020 and March 2021. The main objective was to detect SARSCoV- 2 outbreaks among residents and study the efficacy of the vaccination campaign. SARS-CoV-2 viral load (RNA copies per L of wastewater) was determined by reverse-transcription quantitative PCR (RT-qPCR) using the quantification cycle (Cq) values for the nucleocapsid (N) gene. Our results showed that the increase in viral load preceded the increase in clinical cases, favoring an early warning system that detects COVID-19 outbreaks in advance, making it possible to contain and stop the transmission of the virus among residents. In addition, the efficacy of the new COVID-19 vaccines was evidenced, since after the vaccination campaign in nursing homes in A Coruña, it was observed that many residents did not present any symptoms of the disease, although they excreted high amounts of virus in their feces. WBE is a cost-effective strategy that should be implemented in all cities to prevent new emerging diseases or future pandemic threats., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604, Funding for open access charge: Universidade da Coruña/CISUG. This work was mainly supported by the grant INV00821 from Consellería de Política Social (Xunta de Galicia, Spain) to M.P. The team was also supported by EDAR Bens S.A., A Coruña, Spain (grant references INV04020, INV12120, INV05921, and INV148721 to M.P.), by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to G.B., PI17/01482 and PI20/00413 to M.P.], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to G.B., ED431C-2016/015 and ED431C-2020/14 to R.C., ED431C 2021/53 to S.L., and ED431G 2019/01 and COV20/00604 to R.C. and S.L., by the Ministry of Economic Affairs and Digital Transformation (MINECO), Spain (grant references MTM2017-82724-R to R.C.), by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII, reference CB21/13/00055), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. S.R.-F. was financially supported by REIPI RD16/0016/006, K.C.-P. by IN607A 2016/22 and the Spanish Association against Cancer (AECC), and J.A.V. by IN607A 2016/22.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Maneiro Rey, María
  • Conde-Pérez, Kelly
  • Álvarez-Fraga, Laura
  • Torrens Ribot, Gabriel
  • Oliver, Antonio
  • Buynak, John
  • Bonomo, Robert
  • Bou, Germán
  • González-Bello, Concepción
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in Acinetobacter baumannii. CHDLs are not effectively inactivated by clinically available β-lactam-type inhibitors. We have previously described the in vitro efficacy of the inhibitor LN-1-255 in combination with carbapenems. The aim of this study was to compare the efficacy of LN-1-255 with that of imipenem in murine pneumonia using A. baumannii strains carrying their most extended carbapenemases, OXA-23 and OXA-24/40. The blaOXA-23 and blaOXA-24/40 genes were cloned into the carbapenem-susceptible A. baumannii ATCC 17978 strain. Clinical isolates Ab1 and JC12/04, producing the enzymes OXA-23 and OXA-24/40, respectively, were used in the study. Pharmacokinetic (PK) parameters were determined. An experimental pneumonia model was used to evaluate the efficacy of the combined imipenem–LN-1-255 therapy. MICs of imipenem decreased between 32- and 128-fold in the presence of LN-1-255. Intramuscular treatment with imipenem–LN-1-255 (30/50 mg/kg) decreased the bacterial burden by (i) 4 and 1.7 log10 CFU/g lung in the infection with the ATCC 17978-OXA-23 and Ab1 strains, respectively, and by (ii) 2.5 and 4.5 log10 CFU/g lung in the infection produced by the ATCC 17978-OXA-24/40 and the JC12/04 strains, respectively. In all assays, combined therapy offered higher protection against pneumonia than that provided by monotherapy. No toxicity was observed in treated mice. Imipenem treatment combined with LN-1-255 treatment significantly reduced the severity of infection by carbapenem-resistant A. baumannii strains carrying CHDLs. Preclinical assays demonstrated the potential of LN-1-255 and imipenem therapy as a new antibacterial treatment., This work has been funded by projects PI15/00860 to G.B., CP13/00226 to A.B., and P14/00059 and PI17/01482 to M.P. and A.B., all of which were integrated into the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe,” The study was also funded by project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. This study was also funded by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation 2016 to 2019, ED431G/09), and by the European Regional Development Fund (ERDF) to C.G.-B. This work was also supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. Also, this study was supported in part by funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (USA) under award numbers R01AI063517, R01AI072219, and R01AI100560, by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award 1I01BX001974, and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. J.D.B. acknowledges support from the National Institutes of Allergy and Infectious Diseases under award number R15AI142699. J.C.V.-U. was financially supported by the Miguel Servet Programme (CP13/00226; ISCIII, Spain) and by Consellería de Cultura, Educación e Ordenación Universitaria (IN607A 2016/22), and M.M.-G. was financially supported by a Clara Roy grant (Spanish Society of Clinical Microbiology and Infectious Diseases [SEIMC])., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institutes of Allergy and Infectious Diseases; R15AI142699
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Oviaño, Marina
  • Álvarez-Fraga, Laura
  • Alonso-García, Isaac
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
Multicenter study, [Abstract] The global distribution of carbapenemases such as KPC, OXA-48, and metallo-β-lactamases (MBLs) gives cause for concern, as these enzymes are not inhibited by classical β-lactamase inhibitors (BLIs). The current development of new inhibitors is one of the most promising highlights for the treatment of multidrug-resistant bacteria. The activity of cefepime in combination with the novel BLIs zidebactam, taniborbactam, and enmetazobactam was studied in a collection of 400 carbapenemase-producing Enterobacterales (CPE). The genomes were fully sequenced and potential mechanisms of resistance to cefepime/BLI combinations were characterized. Cefepime resistance in the whole set of isolates was 79.5% (MIC50/90 64/≥128mg/L). The cefepime/zidebactam and cefepime/taniborbactam combinations showed the highest activity (MIC50/90 ≤0.5/1 and ≤0.5/2 mg/L, respectively). Cefepime/zidebactam displayed high activity, regardless of the carbapenemase or extended-spectrum β-lactamase (ESBL) considered (99% of isolates displayed MIC ≤2 mg/L). Cefepime/taniborbactam displayed excellent activity against OXA-48- and KPC-producing Enterobacterales and lower activity against MBL-producing isolates (four strains yielded MICs ≥16 mg/L: 2 NDM producers with an insertion in PBP3, one VIM-1 producer with nonfunctional OmpK35, and one IMP-8 producer). Cefepime/enmetazobactam displayed the lowest activity (MIC50/90 1/≥128 mg/L), with MICs ≥16 mg/L for 49 MBL producers, 40 OXA-48 producers (13 with amino acid changes in OmpK35/36, 4 in PBPs and 11 in RamR) and 25 KPC producers (most with an insertion in OmpK36). These results confirm the therapeutic potential of the new β-lactamase inhibitors, shedding light on the activity of cefepime and BLIs against CPE and resistance mechanisms. The cefepime/zidebactam and cefepime/taniborbactam combinations are particularly highlighted as promising alternatives to penicillin-based inhibitors for the treatment of CPE., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 for G.B. integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III, ISCIII).CIBERINF (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), N° RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Seoane-Estévez, Alejandro
  • Rodiño-Janeiro, Bruno Kotska
  • González-Bardanca, Mónica
  • Conde-Pérez, Kelly
  • Martínez Guitián, Marta
  • Álvarez-Fraga, Laura
  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background: Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives: To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying β-lactam resistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain. Materials and methods: Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. β-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS. Results: For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/≥256 mg/L) were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = ≤0.25/1 mg/L), respectively. The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC). Conclusions: Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B. and PI17/01482, PI20/01212 to A.B.) integrated in the Plan Nacional de I + D and funded by the Instituto de Salud Carlos III (ISCIII). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe’.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

  • Alonso-García, Isaac
  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • González-Mayo, Elena
  • Lada-Salvador, Paula
  • Vela-Fernández, Ramón
  • Aja-Macaya, Pablo
  • Guijarro-Sánchez, Paula
  • Rumbo-Feal, Soraya
  • Muíño-Andrade, María José
  • Fernández González, Ana
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Galán-Sánchez, Fátima
  • Bou, Germán
[Abstract] Objectives: To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection. Methods: One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays. Results: Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility. Conclusions: We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI22/01212 for J.A.-S., PI17/01482 and PI20/01212 for A.B., PI21/00017 for A.O., and PI18/00501 and PI21/00704 for G.B. integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III, ISCIII). This research was also funded by CIBERINFEC, no. CB21/13/00055 and no. CB21/13/00099 (CIBER de Enfermedades Infecciosas), and by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) ‘A way of making Europe’. The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12 to A.B. and IN607A 2016/22 to G.B.). I.A.-G was financially supported by the Rio Hortega programme (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026)., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniae

  • Poza, Margarita
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Conde-Pérez, Kelly
  • Arca-Suárez, Jorge
  • Álvarez-Fraga, Laura
  • Pérez Gómez, Astrid
  • Crecente-Campo, José
  • Alonso, María J.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] The discovery of new antibiotics that are effective against Acinetobacter baumannii and Enterobacteralesis a research priority. Several essential oils (EOs) have displayed some antimicrobial activity and could potentially act as antibiotic adjuvants. Research in this area aims to develop new therapeutic alternatives to treat infections caused by these pathogens. MICs of different EOs were determined against A. baumannii and Klebsiella pneumoniae. Combined disk diffusion tests and checkerboard assays were used to study the synergy between the EOs and antibiotics. The fractional inhibitory concentration index (FICindex) was calculated in order to categorize the interaction. Time-kill assays were also performed. The EOs that displayed the highest levels of antimicrobial activity were clove (Syzygium aromaticum L.) and thyme (Thymus zygis L.). Combined disk diffusion tests and checkerboard assays revealed synergy between these EOs and colistin. Addition of either clove or thyme EO decreased the MIC of colistin by 8- to 64-fold and 8- to 128-fold in the colistin-resistant A. baumannii and K. pneumoniae strains, respectively (FICindex ≤ 0.5, synergy). MICs were also reduced in the colistin-susceptible strains. Time-kill assays also indicated the strong activity of the combined therapy. In summary, the use of clove or thyme EO in combination with colistin could improve the efficacy of the antibiotic and significantly reduce the concentrations needed to inhibit growth of A. baumannii and K. pneumoniae., Funding: This study was funded by projects IN607A 2016/22 (GAIN), PI15/00860, PI18/00501 and REIPI RD16/0016/006 (co-financed by the European Development Regional Fund "A way to achieve Europe" and the operative Intelligent Growth program 2014-2020) awarded to GB, PI14/00059 and PI17/01482 awarded to AB and MP (Instituto de Salud Carlos III). JCVU was financially supported the pFIS Programme (FI18/00315, ISCIII), MMG by a Clara Roy grant (SEIMC), KCP by IN607A 2016/22 (GAIN), CLM by IN606A-2019/029 (GAIN) and JAS by the Rio Hortega program (CM19/00219, ISCIII) and the FPNS (post-specialization grant). Acknowledgements: We thank Dr J.D. Boyce for the kind gift of ATCC19606ΔlpxC. We also thank Dr S. Pournaras for the kind gift of AB248 and AB249.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antimicrobial activity of Cefiderocol against the Carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with Metallo-β-Lactamase VIM-1

  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Álvarez-Fraga, Laura
  • Outeda-García, Michelle
  • Martínez Guitián, Marta
  • Peña-Escolano, Andrea
  • Maceira, Romina
  • Lence, Emilio
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Emergence of cefiderocol resistance among carbapenemase-producing Enterobacterales, particularly those in the Enterobacter cloacae complex (ECC), is becoming of alarming concern; however, the mechanistic basis of this phenomenon remains poorly understood. We describe the acquisition of VIM-1-mediated reduced cefiderocol susceptibility (MICs 0.5 to 4 mg/L) in a collection of 54 carbapenemase-producing isolates belonging to the ECC. MICs were determined by reference methodologies. Antimicrobial resistance genomic analysis was performed through hybrid WGS. The impact of VIM-1 production on cefiderocol resistance in the ECC background was examined at microbiological, molecular, biochemical, and atomic levels. Antimicrobial susceptibility testing yielded 83.3% susceptible isolates and MIC50/90 values of 1/4 mg/L. Decreased susceptibility to cefiderocol was mainly associated with isolates producing VIM-1, with cefiderocol MICs 2- to 4-fold higher than for isolates carrying other types of carbapenemases. E. cloacae and Escherichia coli VIM-1 transformants displayed significantly enhanced cefiderocol MICs. Biochemical assays with purified VIM-1 protein revealed low but detectable cefiderocol hydrolysis. Simulation studies revealed how cefiderocol is anchored to the VIM-1 active site. Additional molecular assays and WGS data analysis highlighted the implication of SHV-12 coproduction and suggested the inactivation of the FcuA-like siderophore receptor as further contributors to the higher cefiderocol MICs. Our findings warn of the potential of the VIM-1 carbapenemase to at least partly limit the activity of cefiderocol in the ECC. This effect is probably enhanced due to combination with additional mechanisms, such as ESBL production and siderophore inactivation, and indicates the need for active surveillance to extend the life span of this promising cephalosporin., This research was supported by Projects PI17/01482 and PI20/01212 awarded to AB, PI22/01212 to JAS and PI18/00501 to GB, within in the National Plan for Scientific Research, Development and Technological Innovation 2017 to 2020 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III). The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación-Consellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. It was also supported by Planes Nacionales de I+D+i2017 to 2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth2014 to 2020. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 Grant (Xunta de Galicia), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O. was financially supported by IN607D 2021/12 (Xunta de Galicia). I.A.-G. was financially supported by the Rio Hortega program (ISCIII, CM21/00076). C.G.-B. acknowledges financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation2019 to 2022 [ED431G 2019/03]), and the European Regional Development Fund (ERDF)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Gómez, Patricia
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Novoa Olmedo, María Lourdes
  • Guillén-Hernández, Sergio
  • Villegas-Hernández, Harold
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] A total of 51 sponges (Porifera) and 13 ascidians (Chordata) were collected on the coast of the Yucatan Peninsula (Mexico) and extracted with organic solvents. The resulting extracts were screened for antibacterial activity against four multidrug-resistant (MDR) bacterial pathogens: the Gram-negative Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa and the Gram-positive Staphylococcus aureus. The minimum inhibitory concentrations (MICs) of the organic extracts of each marine organism were determined using a broth microdilution assay. Extracts of eight of the species, in particular the Agelas citrina and Haliclona (Rhizoniera) curacaoensis, displayed activity against some of the pathogens tested. Some of the extracts showed similar MIC values to known antibiotics such as penicillins and aminoglycosides. This study is the first to carry out antimicrobial screening of extracts of marine sponges and ascidians collected from the Yucatan Peninsula. Bioassay-guided fractionation of the active extracts from the sponges Amphimedon compressa and A. citrina displayed, as a preliminary result, that an inseparable mixture of halitoxins and amphitoxins and (-)-agelasine B, respectively, are the major compounds responsible for their corresponding antibacterial activities. This is the first report of the antimicrobial activity of halitoxins and amphitoxins against major multidrug-resistant human pathogens. The promising antibacterial activities detected in this study indicate the coast of Yucatan Peninsula as a potential source of a great variety of marine organisms worthy of further research., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union, by projects PI15/00860 and PI18/00501 to GB and PI14/00059 and PI17/01482 to AB (Instituto de Salud Carlos III) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) and GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). Support was also provided by Planes Nacionales de I+D+i 2013-2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund "A way to achieve Europe" and the operative program Intelligent Growth 2014-2020. J.C.V.U. was financially supported by the pFIS Programme (FI18/00315), M.M.G. was financially supported by a Clara Roy grant (SEIMC) and C.L.M. by IN606A-2019/029. D.P.P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Kpi, a Chaperone-Usher Pili System Associated with the Worldwide-Disseminated High-Risk Clone Klebsiella Pneumoniae ST-15

  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Rumbo-Feal, Soraya
  • Álvarez-Fraga, Laura
  • Vallejo, J. A.
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Ramos Vivas, Jose
  • Sola-Campoy, Pedro Juan
  • Pérez-Vázquez, María
  • Oteo, Jesús
  • Rodiño-Janeiro, Bruno Kotska
  • Romero, A.
  • Poza, Margarita
  • Bou, Germán
  • Pérez Gómez, Astrid
[Abstract] Control of infections caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging. The success of this pathogen is favored by its ability to acquire antimicrobial resistance and to spread and persist in both the environment and in humans. The emergence of clinically important clones, such as sequence types 11, 15, 101, and 258, has been reported worldwide. However, the mechanisms promoting the dissemination of such high-risk clones are unknown. Unraveling the factors that play a role in the pathobiology and epidemicity of K. pneumoniae is therefore important for managing infections. To address this issue, we studied a carbapenem-resistant ST-15 K. pneumoniae isolate (Kp3380) that displayed a remarkable adherent phenotype with abundant pilus-like structures. Genome sequencing enabled us to identify a chaperone-usher pili system (Kpi) in Kp3380. Analysis of a large K. pneumoniae population from 32 European countries showed that the Kpi system is associated with the ST-15 clone. Phylogenetic analysis of the operon revealed that Kpi belongs to the little-characterized γ2-fimbrial clade. We demonstrate that Kpi contributes positively to the ability of K. pneumoniae to form biofilms and adhere to different host tissues. Moreover, the in vivo intestinal colonizing capacity of the Kpi-defective mutant was significantly reduced, as was its ability to infect Galleria mellonella. The findings provide information about the pathobiology and epidemicity of Kpi+ K. pneumoniae and indicate that the presence of Kpi may explain the success of the ST-15 clone. Disrupting bacterial adherence to the intestinal surface could potentially target gastrointestinal colonization., This research was supported by Projects p-01216A and IJCI-2016-29524 (to A.P.), funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Minestry of Economy and Competetiveness (MINECO), respectively. It was also supported by Projects PI11/01034 (to M.P.), PI14/00059 and PI17/1482 (to M.P. and A.B.), and PI18/00501 (to G.B.), included in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the Instituto de Salud Carlos III (ISCIII) and Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014-2020. Grant BFU2016-77835-R of the MINECO (to A.R.) also supported this research. E.G. was financially supported by the SEIMC project. J.C.V.-U. was financially supported by the PFIS (Contratos Predoctorales de Formación en Investigación en Salud) program (F18/00315); J.A.V. was financially supported by IN607A 2016/22; M.M.-G. was financially supported by a Clara Roy grant (SEIMC); A.B. was financially supported by the Miguel Servet program (ISCIII, Spain); B.K.R.-J. was financially supported by Marie S. Curie Action SaPhaDe project (MSCA-IF-GF-836754); and A.P. was financially supported by the Juan de la Cierva program (MINECO, IJCI-2016-29524), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; p-01216A, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Pneumonia infection in mice reveals the involvement of the feoA gene in the pathogenesis of Acinetobacter baumannii

  • Poza, Margarita
  • Álvarez-Fraga, Laura
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Vallejo, J. A.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Acinetobacter baumannii has emerged in the last decade as an important nosocomial pathogen. To identify genes involved in the course of a pneumonia infection, gene expression profiles were obtained from A. baumannii ATCC 17978 grown in mouse infected lungs and in culture medium. Gene expression analysis allowed us to determine a gene, the A1S_0242 gene (feoA), over-expressed during the pneumonia infection. In the present work, we evaluate the role of this gene, involved in iron uptake. The inactivation of the A1S_0242 gene resulted in an increase susceptibility to oxidative stress and a decrease in biofilm formation, in adherence to A549 cells and in fitness. In addition, infection of G. mellonella and pneumonia in mice showed that the virulence of the Δ0242 mutant was significantly attenuated. Data presented in this work indicated that the A1S_0242 gene from A. baumannii ATCC 17978 strain plays a role in fitness, adhesion, biofilm formation, growth, and, definitively, in virulence. Taken together, these observations show the implication of the feoA gene plays in the pathogenesis of A. baumannii and highlight its value as a potential therapeutic target., This work has been funded by Projects PI15/00860 to GB, CP13/00226 to AB, PI11/01034 to MP and P14/00059 and PI17/01482 to MP and AB, all integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by the project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. Also supported by Planes Nacionales de I+D+i 2008–2011 / 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 and REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J. A. Vallejo was financially supported by the Sara Borrell Programme (ISCIII, Spain CD13/00373), J.C. Vázquez-Ucha was financially supported by the Miguel Servet Programme (ISCIII, Spain CP13/00226) and M. Martínez-Guitián was financially supported by the grant Clara Roy (Spanish Society of Clinical Microbiology and Infectious Diseases). We thank M. I. Voskuil (Dept. of Immunology and Microbiology, University of Colorado Medical School, CO, USA) for providing pMo130., Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria; IN607A 2016/22